Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2
about
The iTRAPs: Guardians of Synaptic Vesicle Cargo Retrieval During EndocytosisAmyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's diseaseCholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic DysfunctionThe Gos28 SNARE protein mediates intra-Golgi transport of rhodopsin and is required for photoreceptor survival.LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses.The elusive nature and diagnostics of misfolded Aβ oligomers.Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1.Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice.Approaches to Investigating Complex Genetic Traits in a Large-Scale Inbred Mouse Aging Study.Neurodegenerative Disease Related Proteins Have Negative Effects on SNARE-Mediated Membrane Fusion in Pathological Confirmation.Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.The Sybtraps: control of synaptobrevin traffic by synaptophysin, α-synuclein and AP-180.Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.The Role of PICALM in Alzheimer's Disease.Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission.MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2.Amyloid-β Oligomers Interact with Neurexin and Diminish Neurexin-mediated Excitatory Presynaptic Organization.Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.Amyloid-β Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission.Synapses in neurodegenerative diseases.Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer's disease.Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.Short general anaesthesia induces prolonged changes in gene expression in the mouse hippocampus.Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer's disease at various cognitive stages.Manganese exposure disrupts SNARE protein complex-mediated vesicle fusion in primary cultured neurons.Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an Aβ1-42 Mouse Model of Alzheimer's Disease.Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention.
P2860
Q26768190-227FD1AB-D138-4533-8A5A-702CF46068EEQ27012950-9DCA876C-18D0-4C0F-8D19-F83387F6C57BQ33607803-EDF3B409-E13C-483D-AF15-B8076BBF028EQ34552505-E7411B28-C3ED-4C6A-B64B-4E7598BB830EQ34643378-50F6E6F1-59B1-4373-A48C-D4A4BAB167AEQ35194588-AE833328-46A5-4202-8302-B7991FD7A7F9Q35589286-DF1846EF-CA8F-40FB-BF9D-0206172D4A85Q36249492-D83079C5-A3B8-4EB6-9DE1-465198922823Q36869427-5CEB71DA-5B55-46E6-9E8C-B9C2288CC6A1Q37479405-C29D0337-6CC2-49FA-8860-2A827A3624C8Q37631135-58D9595C-3F5B-4CB1-8DAE-90EFA41953ACQ37712556-3D3CF6C9-D741-4B41-B4EA-EB068D9A6C61Q38106483-E3A0BC3A-70B5-4EF6-8032-D75B1BD4D24AQ38166437-4F59E339-E793-4A8D-9C41-4DCF341E1654Q38203031-9D6A2248-09EA-48F4-BEB3-9532300CE2F5Q38245888-8BCDDD99-D8F8-4F13-8E1A-1C5B5B5FF92EQ38502400-BA98891D-89B9-454D-9434-E7EB0E618C19Q38832895-E9D68EFC-06EA-4A4A-81D2-7D5C11D85DAEQ38955415-AC712F1D-9204-445D-914A-5D2295BB9662Q39164408-106DC7B0-E2D4-4F25-83F8-C47310F4298BQ41025036-AD3C9853-9A50-4AB9-BDD5-1095F11B429DQ42342648-059E6A58-168A-4861-B8BC-42874B279937Q44763772-3B8246AF-C10F-4462-A18A-D1EF9146F2E0Q47443049-1753A757-7D87-4C17-B094-3434777B8481Q47841175-E57F3923-476C-49E0-A0D5-06FF3873FA0AQ48223342-1BEE07DC-CFFC-4B1E-9002-E6C0E0ED0F29Q48787082-B9BB83EC-9C2F-46AC-997C-046D7E02BBE7Q49256155-41D84D2F-C332-48E4-9DC6-63B9DF9D6F51Q50620823-0DCCC1E1-1018-462A-A220-F355337AC69FQ53513746-B553C185-CA3C-4EA7-91A2-BC8B348B1A39
P2860
Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@ast
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@en
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@nl
type
label
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@ast
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@en
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@nl
prefLabel
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@ast
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@en
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@nl
P2093
P2860
P1433
P1476
Amyloid-β acts as a regulator ...... etween synaptophysin and VAMP2
@en
P2093
Brian M Austen
Claire L Russell
Philip W Beesley
Sophia Semerdjieva
P2860
P304
P356
10.1371/JOURNAL.PONE.0043201
P407
P577
2012-01-01T00:00:00Z